Entrada Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Entrada Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Entrada Therapeutics Inc
Rating: 1.40491675
Author: Trendlyne DVM scores

about

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosoma...

5.28 -0.05 (-0.94%)

75.77% Fall from 52W High

244.3K

XNAS Volume

XNAS 12 Sep, 2025 5:30 PM (EDT)

Not Eligible

Expensive Valuation

27.7 / 100

Technically Bearish

28.5 / 100

1Yr Price target upside is 250%

2 analysts

Entrada Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Entrada Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosoma...

75.77% Fall from 52W High

SWOT Analysis

Entrada Therapeutics Inc Live Price Chart